Abstracts tagged "interstitial lung disease and rheumatoid arthritis (RA)"

Abstract Number: 2347 • 2019 ACR/ARP Annual Meeting
Long-term Survival in Lung Transplantation and Allograft Rejection in Patients with Interstitial Lung Disease Related with Rheumatoid Arthritis: Study from a Single Referral Center
DIANA PRIETO- PENA¹, Amaya Martinez Meñaca ², Mónica Calderón-Goercke ³, Victor Manuel Mora Cuesta ⁴, Sonia M. Fernández Rozas ⁴, David Iturbe Fernandez ², Iñigo Gonzalez-Mazon ¹, Lara Sanchez-Bilbao ⁵, Jose Manuel Cifrian Martínez ⁴, Miguel Angel González-Gay ⁶ and Ricardo Blanco ⁵, ¹Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, ⁴Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL; and Pneumology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain, Santander, Spain, ⁵Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain, ⁶Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of death in patients with rheumatoid arthritis (RA). In end-stage RA-ILD, lung transplant becomes the only…
Abstract Number: 542 • 2018 ACR/ARHP Annual Meeting
Incidence and Prevalence of Interstitial Lung Disease in the US Population and in Patients with RA By Anti-Citrullinated Protein Antibody Status
Evo Alemao¹, Roshini Indrakumar², Aarti Rao² and Ying Bao¹, ¹Bristol-Myers Squibb, Princeton, NJ, ²Mu Sigma, Bangalore, India
Background/Purpose: Interstitial lung disease (ILD) is recognized as the most common pulmonary extra-articular manifestation of RA. The hazard ratio for 30-year risk of ILD in…
Abstract Number: 1819 • 2018 ACR/ARHP Annual Meeting
MUC5B promoter Variant rs35705950 Is a Risk Factor for Rheumatoid Arthritis – Interstitial Lung Disease
Pierre-Antoine Juge¹, Joyce Sujin Lee², Esther Ebstein¹, Hiroshi Furukawa³, Evgenia Dobrinskikh⁴, Steven Gazal⁵, Caroline Kannengiesser⁵, Sébastien Ottaviani¹, Shomi Oka⁶, Shigeto Tohma⁷, Naoyuki Tsuchiya⁸, Jorge Rojas-Serrano⁹, Montserrat I. González-Pérez⁹, Mayra Mejía⁹, Ivette Buendía-Roldán⁹, Ramcés Falfan-Valencia¹⁰, Enrique Ambrocio-Ortiz¹⁰, Effrosyni Manali¹¹, Spyros A. Papiris¹¹, Theofanis Karageorgas¹², Dimitrios Boumpas¹², Katarina Antoniou¹³, Coline H.M. van Moorsel¹⁴, Joanne van der Vis¹⁴, Yaël A. de Man¹⁴, Jan C. Grutters¹⁴, Yaping Wang¹⁵, Raphaël Borie¹⁶, Lidwine Wemeau-Stervinou¹⁷, Benoit Wallaert¹⁸, René-Marc Flipo¹⁹, Hilario Nunes²⁰, Dominique Valeyre²⁰, Nathalie Saidenberg²¹, Marie-Christophe Boissier²², Sylvain Adam-Marchand²³, Aline Frazier²⁴, Pascal Richette²⁵, Yannick Allanore²⁶, Jean Sibilia²⁷, Claire Dromer²⁸, Christophe Richez²⁹, Thierry Schaeverbeke³⁰, Huguette Lioté³¹, Gabriel Thabut³², Nadia Nathan³³, Serge Amselem³⁴, Martin Soubrier³⁵, Vincent Cottin³⁶, Annick Clément³³, Kevin D. Deane³⁷, Avram D. Walts⁴, Tasha Fingerlin³⁸, Aryeh Fischer³⁹, Jay H. Ryu⁴⁰, Eric L. Matteson⁴¹, Timothy B. Niewold⁴², Deborah Assayag⁴³, Andrew Gross⁴⁴, Paul Wolters⁴⁵, Marvin I. Schwartz⁴⁶, V. Michael Holers⁴⁷, Joshua J. Solomon⁴⁸, Tracy Doyle⁴⁹, Ivan O. Rosas⁵⁰, Cornelis Blauwendraat⁵¹, Mike A. Nalls⁵², Marie-Pierre Debray¹⁶, Catherine Boileau⁵, Bruno Crestani¹⁶, David A. Schwartz⁴ and Philippe Dieude¹⁶, ¹Rhumatologie, Hôpital Bichat - Claude Bernard, Paris, France, ²SOM-MED, University of Colorado, Denver - Anschutz Medical Campus, Aurora, CO, ³University of Tsukuba, Graduate School of Comprehensive Human Sciences, Masters' Program in Medical Sciences, Tsukuba, Japan, ⁴Department of Medicine, University of Colorado School of Medicine, Aurora, CO, ⁵Génétique, Hôpital Bichat - Claude Bernard, Paris, France, ⁶Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hopsital, Sagamihara, Japan, ⁷Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan, ⁸Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ⁹Interstitial Lung Disease & Rheumatology Unit, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico, ¹⁰HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico, ¹¹2nd Pulmonary Medicine Department, University Hospital of Athens "Attikon", Athens, Greece, ¹²Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, University Hospital of Athens "Attikon", Athens, Greece, ¹³PS Department of Respiratory Medicine & Laboratory of Molecular & Cellular Pneumonology, University of Crete, Crete, Greece, ¹⁴St Antonius ILD center of excellence, St Antonius ziekenhuis, Nieuwegein, Netherlands, ¹⁵Department of Medical Genetics, Nanjing University School of Medicine, Nanjing, China, ¹⁶Université Paris-Diderot, Paris, France, ¹⁷Pneumologie, CHRU de Lille, Lille, France, ¹⁸Pneumology, CHRU, Lille CEDEX, France, ¹⁹Hôpital Roger Salengro, Lille, France, ²⁰Pulmonary diseases department, Avicenne Hospital (AP-HP), Bobigny, France, ²¹Rhumatologie, Hôpital Avicenne, Paris, France, ²²74 rue Marcel Cachin, INSERM, Bobigny, France, ²³Pneumology, Centre Hospitalier Universitaire de Tours, Tours, France, ²⁴Rhumatologie, Hôpital Lariboisière, Paris, France, ²⁵Rheumatology, Université Paris Diderot, Paris, France, ²⁶Rhumatologie A, Hôpital Cochin, Paris, France, ²⁷Université de Strasbourg, Strasbourg, France, ²⁸Imagerie Thoracique et Cardiovasculaire, CHU Bordeaux, Bordeaux, France, ²⁹Department of Rheumatology, Bordeaux University Hospital, Bordeaux, France, ³⁰Department of Rheumatology, Bordeaux University Hospital, BORDEAUX, France, ³¹Pneumologie A, Hôpital Tenon, Paris, France, ³²Pneumologie B, Hôpital Bichat - Claude Bernard, Paris, France, ³³Pneumologie pédiatrique, Hôpital Trousseau, Paris, France, ³⁴Service de Pneumologie Pédiatrique et Centre de référence des maladies respiratoires rares, Hôpital Trousseau, Paris, France, ³⁵Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ³⁶Lyon Louis Pradel, Lyon, France, ³⁷Division of Rheumatology, University of Colorado Denver, Aurora, CO, ³⁸Department of Biomedical Research, National Jewish Health, Denver, CO, ³⁹Rheumatology / ILD Program, National Jewish Health, Denver, CO, ⁴⁰Division of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁴¹Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁴²Colton Center for Autoimmunity, New York University School of Medicine, New York, NM, ⁴³McGill University, Department of Medicine, Montreal, QC, Canada, ⁴⁴Department of Medicine, University of California, San Francisco, CA, ⁴⁵Pulmonary Division, Department of Medicine, University of California, San Francisco, San Francisco, CA, ⁴⁶University of Colorado School of Medicine, Department of Medicine, Aurora, CO, ⁴⁷Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁴⁸Division of Pulmonary and Critical Care Medicine, National Jewish Health, Denver, CO, ⁴⁹Brigham and Women's Hospital, Boston, MA, ⁵⁰BWH - Pulmonary, Brigham and Women's Hospital, Boston, MA, ⁵¹Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD, ⁵²Data Tecnica International, Glen Echo, MD
Background/Purpose: Given phenotypic similarities between rheumatoid arthritis–associated interstitial lung disease (RA-ILD) and idiopathic pulmonary fibrosis (IPF), we hypothesized that the strongest risk factor for the…
Abstract Number: 2045 • 2018 ACR/ARHP Annual Meeting
Specific Anti-Citrullinated Protein Antibodies Profiles Are Associated with Rheumatoid Arthritis Related Interstitial Lung Disease
Pierre-Antoine Juge¹, Leonor Nogueira², Guy Serre², René-Marc Flipo³, Lidwine Wemeau-Stervinou⁴, Thierry Schaeverbeke⁵, Claire Dromer⁶, Sylvain Adam-Marchand⁷, Marie-Christophe Boissier⁸, Hilario Nunes⁹, Raphaël Borie¹⁰, Bruno Crestani¹⁰ and Philippe Dieude¹⁰, ¹Rhumatologie, Hôpital Bichat - Claude Bernard, Paris, France, ²Unité Différenciation Épidermique et Autoimmunité Rhumatoïde, Unité Mixte de Recherche, INSERM, Toulouse, France, ³Hôpital Roger Salengro, Lille, France, ⁴Pneumologie, CHRU de Lille, Lille, France, ⁵Department of Rheumatology, Bordeaux University Hospital, BORDEAUX, France, ⁶Imagerie Thoracique et Cardiovasculaire, CHU Bordeaux, Bordeaux, France, ⁷Pneumology, Centre Hospitalier Universitaire de Tours, Tours, France, ⁸74 rue Marcel Cachin, INSERM, Bobigny, France, ⁹Pulmonary diseases department, Avicenne Hospital (AP-HP), Bobigny, France, ¹⁰Université Paris-Diderot, Paris, France
Background/Purpose: The identification of peripheral blood markers of rheumatoid arthritis-associated interstitial lung disease (RA-ILD) may facilitate an earlier diagnosis and provide insight regarding the pathogenesis…
Abstract Number: 523 • 2018 ACR/ARHP Annual Meeting
The Prevalence and Clinical Characteristics of Rheumatoid Arthritis with Interstitial Lung Disease in the San Joaquin Valley of Central California
Candice Yuvienco¹, Matthew White², Kyle Heber³ and Ratnali Jain², ¹Internal Medicine, Division of Rheumatology, University of California San Francisco, Fresno Medical Education Program, Fresno, CA, ²Internal Medicine, University of California San Francisco - Fresno Medical Education Program, Fresno, CA, ³IM, UCSF Fresno, Fresno, CA
Background/Purpose: Rheumatoid Arthritis (RA) is an autoimmune disease of systemic inflammation primarily involving the small synovial joints. Approximately 1.5 million adults in the United States…
Abstract Number: 524 • 2018 ACR/ARHP Annual Meeting
Clinical Course of Interstitial Lung Disease in Rheumatoid Arthritis Patients in Clinical Practice
Cristina Vadillo Font¹, María A Nieto², Dalifer Freites Núñez³, Zulema Rosales Rosado^1,3, Leticia Leon³, Judit Font Urgelles¹, Juan A Jover Jover¹ and Lydia A Alcazar³, ¹Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ²Chest diseases, Hospital Clínico San Carlos, Madrid, Spain, ³Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain
Background/Purpose: Interstitial lung disease (ILD) is the extra-articular manifestation that most frequently worsens the course of Rheumatoid arthritis (RA) disease. Purpose: To describe the characteristics…
Abstract Number: 527 • 2018 ACR/ARHP Annual Meeting
Long-Term Follow up of Subclinical Interstitial Lung Disease in Rheumatoid Arthritis
Masaomi Yamasaki, Rheumatology, Shin-Yokohama Arthritis and Rheumatology Clinic, Yokohama, Japan
Background/Purpose: Using of high-resolution computed tomography(HRCT) has increased the early detection of interstitial lung disease(ILD) in asymptomatic and undiagnosed individuals. This study was to identify…
Abstract Number: 137 • 2017 ACR/ARHP Annual Meeting
Rheumatoid Arthritis and the Risk for Interstitial Lung Disease: A Comparison of Risk Associated with Biologic and Conventional Dmards
Fenglong Xie¹, Narender Annapureddy², Lang Chen¹, Jason Leonard Lobo³, Jim C. Oates⁴, Ankoor Shah⁵, Huifeng Yun⁶, Shuo Yang¹ and Jeffrey R. Curtis⁷, ¹Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Vanderbilt University Medical Center, Nashville, TN, ³Med-Pulmonary, University of North Carolina, Chapel Hill, NC, ⁴Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ⁵Medicine, Duke University Medical Center, Durham, NC, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Interstitial Lung Disease (ILD) is a rare but often severe consequence of several rheumatologic conditions including rheumatoid arthritis (RA). The comparative risk of incident…
Abstract Number: 478 • 2017 ACR/ARHP Annual Meeting
Ectopic Lymphoid Tissue in the Lung Is Uniquely Associated with the ACPA IgA Isotype Even in Absence of Classifiable RA
Lindsay B. Kelmenson¹, M. Kristen Demoruelle¹, Carlyne D. Cool² and Kevin D. Deane¹, ¹Rheumatology Division, University of Colorado Denver, Aurora, CO, ²Pathology, University of Colorado Denver, Aurora, CO
Background/Purpose: Antibodies to citrullinated protein antigens (ACPA) precede the development of rheumatoid arthritis (RA) and may be generated in the lung of established and preclinical…
Abstract Number: 2009 • 2017 ACR/ARHP Annual Meeting
Quantitative Radiographic Analysis of Interstitial Lung Disease Associated with Rheumatoid Arthritis
Jeong Seok Lee¹, Hyun J. Grace Kim², Jonathan Goldin³, Wonho Lee¹, You-Jung Ha⁴, Eun Ha Kang⁴, Yun Jong Lee⁵, Yeong Wook Song⁶ and Eun Young Lee⁷, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South), ²Department of Radiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, ³University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴Division of Rheumatology, Department of Internal Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of (South), ⁵Department of Internal Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of (South), ⁶Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University, Seoul, Korea, Republic of (South), ⁷Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South)
Background/Purpose: Quantitative analysis of fibrotic patterns provides an objective measurement of treatment efficacy in interstitial lung disease (ILD). We aimed to measure the extent of…
Abstract Number: 2915 • 2017 ACR/ARHP Annual Meeting
Increased Expression of Malondialdehyde-Acetaldehyde Adducts (MAA) and Anti-Maa Antibody in Rheumatoid Arthritis-Interstitial Lung Disease
Bryant R. England¹, Geoffrey M. Thiele², Michael J. Duryee³, Dana P. Ascherman⁴, Liron Caplan⁵, M. Kristen Demoruelle⁶, Kevin D. Deane⁵ and Ted R. Mikuls⁷, ¹Division of Rheumatology & Immunology, Department of Internal Medicine, Nebraska-Western IA VA Health Care System & University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁴Medicine/Rheumatology, University of Miami Miller School of Medicine, Miami, FL, ⁵Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁶1775 Aurora Ct, 1775 Aurora Ct, Aurora, CO, ⁷Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Generated under oxidative stress, malondialdehyde-acetaldehyde adducts (MAA), and antibody responses to MAA appear to facilitate loss of immune tolerance and generate pro-inflammatory responses in…
Abstract Number: 576 • 2016 ACR/ARHP Annual Meeting
Anti-CCP3.1 and Anti-CCP3-IgA Are Elevated in RA-Free Subjects with Idiopathic Pulmonary Fibrosis
Scott Matson¹, Joshua J. Solomon², Jeffrey J. Swigris², Jonathan Chung³, Michael Mahler⁴, Kevin D. Deane⁵ and M. Kristen Demoruelle⁵, ¹Medicine, University of Colorado Denver, Aurora, CO, ²Division of Pulmonary and Critical Care Medicine, National Jewish Health, Denver, CO, ³Radiology, University of Chicago Medical Center, Chicago, IL, ⁴Research and Development, Inova Diagnostics, San Diego, CA, ⁵Rheumatology Division, University of Colorado Denver, Aurora, CO
Background/Purpose: In RA-associated interstitial lung disease (RA-ILD), higher levels of anti-CCP antibodies have been associated with the presence and severity of ILD suggesting a potential…
Abstract Number: 1498 • 2016 ACR/ARHP Annual Meeting
Patterns of Interstitial Lung Disease and Associated Mortality in Rheumatoid Arthritis
Alex Zamora-Legoff¹, Cynthia S. Crowson², Megan Krause³, Jay H. Ryu⁴ and Eric L. Matteson³, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic, Rochester, MN, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN
Background/Purpose: To characterize a cohort of patients with rheumatoid arthritis (RA) who have interstitial lung disease (ILD) and to assess the utility of the GAP…
Abstract Number: 1500 • 2016 ACR/ARHP Annual Meeting
Concomitant Development of Interstitial Pneumonia Associated with Dermatomyositis and Rheumatoid Arthritis
Takeshi Shoda^1,2, Tohru Takeuchi³, Kentaro Isoda⁴, Takao Kiboshi⁴ and Shigeki Makino³, ¹Division of Clinical Immunology and Rheumatology, Osaka medical college, Osaka, Japan, ²Department of Rheumatology, Yodogawa Christian Hospital, Osaka, Japan, ³Osaka medical college, Osaka, Japan, ⁴Yodogawa Christian Hospital, Osaka, Japan
Background/Purpose: A few cases of the concomitant development of interstitial pneumonia associated with dermatomyositis (DM-IP) and rheumatoid arthritis (RA) have been reported mainly in Asia,…
Abstract Number: 616 • 2015 ACR/ARHP Annual Meeting
Risk Factors for the Exacerbation of Interstitial Lung Disease (ILD) after Administration of Biologic Dmards in RA Patients with Pre-Existing ILD
Tamao Nakashita¹, Akira Dibatake², Kotaro Matsumoto³, Yoto Hamada⁴ and Shinji Motojima⁵, ¹Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa-city, Japan, ²Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa, Japan, ³Department of Rheumatology and Allergy, Kameda Medical Center, kamogawa, Japan, ⁴Department of Rheumatology and Allergy, Kameda Medical Center, Kamogwa, Japan, ⁵Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa city, Japan
Background/Purpose: Interstitial lung disease (ILD) associated with RA is a big concern particularly in Japanese patients evidenced by the reports that the cause of death…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].